Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Its news flow centers on the clinical and regulatory progress of its lead drug candidate, PrimeC, a novel extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, in a fixed dose designed to target multiple disease mechanisms.
News updates for NRSN commonly cover milestones in ALS and Alzheimer’s clinical programs. These include Phase 2 and Phase 2b trial readouts, such as the PARADIGM study in ALS and the RoAD proof-of-concept study in Alzheimer’s disease, along with biomarker analyses that the company uses to interpret treatment effects. Press releases also highlight safety and tolerability findings, including reports of favorable safety profiles and absence of new or unexpected safety signals in clinical studies.
Investors and observers can expect coverage of regulatory interactions, such as FDA clearance to initiate a pivotal Phase 3 trial of PrimeC in ALS, database lock announcements for Alzheimer’s trials, and updates on planned submissions to agencies like Health Canada. Corporate and financing developments, including private placements of ordinary shares and business updates, are also frequent topics.
This news page aggregates these company-issued announcements, SEC-related communications and other public disclosures about NeuroSense’s progress. It is useful for readers who want to follow NRSN’s clinical trial milestones, biomarker-driven research updates, regulatory steps and capital-raising activities as the company advances PrimeC in ALS and Alzheimer’s disease.
NeuroSense Therapeutics (Nasdaq: NRSN) has regained compliance with Nasdaq's minimum bid price requirement. The company, which develops treatments for severe neurodegenerative diseases, received notice from Nasdaq confirming that it has met the Rule 5550(a)(2) criteria. To achieve this, NeuroSense's ordinary shares maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, accomplished on September 20, 2024.
CEO Alon Ben-Noon expressed satisfaction with this development, viewing it as an important step that reflects the company's commitment to advancing PrimeC. He also mentioned positive momentum following Phase 2b trial results and plans to initiate a Phase 3 trial in the US, along with ongoing discussions with potential partners.
NeuroSense Therapeutics (Nasdaq: NRSN) has received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company's ordinary shares have traded below $1.00 for 30 consecutive trading days. NeuroSense has until February 24, 2025, to regain compliance by maintaining a closing bid price of $1.00 or above for a minimum of 10 consecutive business days.
If compliance is not achieved by the deadline, NeuroSense may be eligible for an additional 180-day period to meet the requirement. The notification does not immediately affect the company's Nasdaq listing or the trading of its shares. However, failure to regain compliance within the allotted time could result in delisting from Nasdaq.
NeuroSense Therapeutics (Nasdaq: NRSN) has announced a private placement of $600,000 in ordinary shares and warrants. The company will sell 800,000 ordinary shares and warrants to purchase an additional 800,000 shares at a combined price of $0.75 per share and accompanying warrant, representing a 10% premium to the closing price on August 6, 2024. The warrants have a five-year term and an exercise price of $0.75 per share.
Notably, senior management, including the CEO, CFO, and CMO, as well as existing shareholders, are participating in the offering. The proceeds will be used for general corporate and working capital purposes. CEO Alon Ben-Noon expressed confidence in PrimeC's potential, citing positive results from the Phase 2b PARADIGM Study for ALS treatment.
NeuroSense Therapeutics (NASDAQ: NRSN) has announced positive 12-month iron biomarker data from its Phase IIb PARADIGM study of PrimeC in ALS patients. The results show significant improvements in iron regulation, aligning with previously reported 36% slower disease progression and 43% improved survival rates. Key findings include a decrease in ferritin levels and an increase in transferrin levels, indicating alleviation of ALS pathology. Iron levels remained stable over the 12-month dosing period, with a mean difference of 4.536 µmol/L compared to the placebo group. These positive changes in iron metabolism correlate with better functionality and survival rates in patients treated with PrimeC. The company is preparing to share additional data with the FDA and is in discussions with potential development partners for marketing opportunities.
NeuroSense has announced positive results from its 12-month PARADIGM Phase 2b study of PrimeC in ALS patients, showing a significant improvement in complication-free survival. Specifically, the study demonstrated a 57% difference in favor of PrimeC over placebo in the ITT population, and a 73% difference in the PP population. PrimeC also slowed disease progression by 36% and improved survival rates by 43% in prior reports. Additional data points showed improvements in Slow Vital Capacity and ALSFRS-R scores. These results will be submitted to the FDA to discuss the future of PrimeC. NeuroSense is optimistic about the potential of PrimeC as a treatment for ALS.
NeuroSense Therapeutics announced promising results from its PARADIGM Phase 2b study on PrimeC for ALS treatment. The 12-month data showed a 36% slower disease progression for participants on PrimeC compared to placebo (p=0.009). PrimeC also improved survival rates by 43%. Further analysis indicated a 40% improvement in ALSFRS-R scores and a 63% boost in survival for the per-protocol population on PrimeC. These findings support advancing to Phase 3 trials in the U.S. and Europe to further evaluate PrimeC's efficacy as a disease-modifying drug for ALS.
NeuroSense Therapeutics (NASDAQ: NRSN) announced a corporate update and Q1 2024 financial results. Their Phase 2b PARADIGM clinical trial showed a significant 43% slowing of disease progression in high-risk ALS patients treated with PrimeC. Upcoming milestones include 12-month clinical results in June 2024 and an FDA meeting in Q3 2024. Financially, the company reported stable R&D and administrative expenses at $1.88M and $1.11M, respectively. However, it faced a net loss of $5.4M for the quarter, with cash reserves at $0.74M as of March 31, 2024. Additional funding of $4.5M was secured in April 2024 through a direct offering.
NeuroSense Therapeutics (Nasdaq: NRSN) has received a delisting notice from Nasdaq due to non-compliance with the minimum $2,500,000 stockholders' equity requirement, as per Listing Rule 5550(b). The company must request a hearing before a Nasdaq Hearings Panel to stay the delisting process. NeuroSense plans to present its compliance strategy during the hearing. The Panel can grant an extension until December 18, 2024, for the company to meet the equity requirement and maintain its listing status.
NeuroSense Therapeutics (NASDAQ: NRSN) announced that its VP of R&D, Dr. Shiran Zimri, will present at the 3rd Annual ALS Drug Development Summit in Boston on May 22, 2024. Dr. Zimri will discuss the potentials of combination therapy in ALS and share the latest progress on PrimeC, NeuroSense's investigational treatment. Recent results from the phase 2b PARADIGM trial showed a 43% slowing of disease progression in high-risk ALS patients treated with PrimeC compared to placebo over 6 months, with a significant 5.04-point difference in ALSFRS-R scores.
NeuroSense Therapeutics (Nasdaq: NRSN) has partnered with PhaseV to optimize its Phase 3 trial of PrimeC for ALS using advanced causal machine learning. PhaseV's analysis of NeuroSense's PARADIGM Phase 2b study predicted high success probabilities in multiple subgroups for the Phase 3 trial. PhaseV's insights will inform study design, patient enrollment, and cost-effectiveness. NeuroSense’s recent Phase 2b data showed PrimeC slowed disease progression by 37% and 43% in high-risk patients. The company plans to submit its End of Phase 2 package to the FDA and EMA soon.